Akebia Therapeutics (AKBA) Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AKBA shares.
View AKBA analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued 1 year price objectives for Akebia Therapeutics' stock. Their AKBA share price forecasts range from $3.75 to $3.75. On average, they expect the company's share price to reach $3.75 in the next twelve months. This suggests a possible upside of 226.1% from the stock's current price.
View analysts price targets for AKBA or view top-rated stocks among Wall Street analysts.

Akebia Therapeutics' stock was trading at $0.5770 at the beginning of 2023. Since then, AKBA shares have increased by 99.3% and is now trading at $1.15.
View the best growth stocks for 2023 here.

Akebia Therapeutics saw a increase in short interest in September. As of September 15th, there was short interest totaling 7,230,000 shares, an increase of 24.4% from the August 31st total of 5,810,000 shares. Based on an average daily volume of 1,760,000 shares, the days-to-cover ratio is currently 4.1 days.
View Akebia Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our AKBA earnings forecast.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) released its quarterly earnings results on Friday, August, 25th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by $0.03. The biopharmaceutical company had revenue of $56.38 million for the quarter, compared to analysts' expectations of $59.10 million. Akebia Therapeutics had a negative net margin of 48.25% and a negative trailing twelve-month return on equity of 249.60%. During the same period in the prior year, the firm posted $0.23 earnings per share.

Invesco Nasdaq Future Gen 200 ETF holds 33,325 shares of AKBA stock, representing 0.72% of its portfolio.

28 employees have rated Akebia Therapeutics Chief Executive Officer John Butler on Glassdoor.com. John Butler has an approval rating of 97% among the company's employees. This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T).

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AKBA stock can currently be purchased for approximately $1.15.

Akebia Therapeutics (NASDAQ:AKBA) has a market capitalization of $216.56 million and generates $201.00 million in revenue each year. The biopharmaceutical company earns $-94,230,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis.

The company employs 204 workers across the globe.

Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The official website for the company is www.akebia.com. The biopharmaceutical company can be reached via phone at (617) 871-2098, via email at ir@akebia.com, or via fax at 617-871-2099.